Quality control requirements in neonatal screening by Torresani, Toni
ARTICLE
Toni Torresani
Quality control requirements in neonatal screening
Published online: 28 November 2003
 Springer-Verlag 2003
Abstract One of the key tasks for the persons in charge
of a neonatal screening laboratory is the control and
maintenance of the quality of analytical results. The
process of examining every day hundreds of blood spot
samples obtained from newborn babies in order to di-
vide the population of neonates into a low risk group
and a high risk group, presents several challenges with
respect to organisation, analytical accuracy and preci-
sion and eﬀectiveness in the recall and treatment pro-
cedures. Quality in neonatal screening is not determined
solely by the analytical performance of the laboratory;
all the steps of the neonatal screening ‘‘system’’ con-
tribute to the overall quality and performance. Con-
clusion: Programmes for the monitoring of the quality of
neonatal screening have to be multidisciplinary and not
restricted to the laboratory alone; not only analytical
performance, but also the procedures used throughout
the programme have to be monitored.
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Introduction
Quality, quality control (QC) and quality assurance
(QA) are very frequently used words in todays health-
care environment. Even if the deﬁnitions of these words
are universal, their application in everyday life must be
customised to the task involved.
For newborn screening (NBS), a public health
activity aimed at the early presymptomatic identiﬁcation
of infants who are aﬀected by certain genetic, metabolic
or infectious conditions, these requirements are partic-
ularly challenging. As one of the best-accepted proce-
dures in preventive paediatric medicine, NBS is the
result of a complex collaborative process. It involves
medical professions, authorities, professional and parent
organisations. All these individuals and interest groups
have to collaborate closely to achieve the goals of NBS.
Table 1 summarises the main components of the NBS
‘‘system’’ and the means used to establish and monitor
quality.
Success or failure, consequently quality, is in such a
process extremely dependent upon the performance
of the weakest component of the NBS ‘‘system’’.
Thus, quality is not a product of coincidence but a well-
planned exercise.
When establishing a NBS programme, the aims to be
achieved must be clearly deﬁned, taking into account the
local infrastructure and the social and political envi-
ronment. These deﬁnitions will determine and inﬂuence
the ﬁnal outcome of the programme. Careful planning
will help enhance quality; the ‘‘obsession’’ to design a
programme aimed at detecting each and every case of a
certain disease, as unfortunately seen in many NBS
programmes worldwide, will most probably result in
poor quality.
Information and education
In the world of NBS, a central role in the planning of
quality is occupied by information and education. A
programme for NBS must be known and accepted in the
general population. This will greatly increase the likeli-
hood that no newborn escapes the sample collection;
thus information and educational activities aimed at the
families and the general public, for example as infor-
mation brochures or radio and TV spots, have proven to
be a good communication vehicle. At the same time,
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NBS must be accepted by the medical professions. By
preparing disease-related guidelines for NBS pro-
grammes, as done for example by the European Society
for Paediatric Endocrinology in the case of congenital
hypothyroidism and congenital adrenal hyperplasia
[1, 2], clear explanations of the aims of the NBS program
can be given and accordingly, rules can be set.
A critical point in NBS is the correct sample collec-
tion. In order to be suitable for NBS, a sample has to be
collected at the right time and with the appropriate
technique, the blood spotted on the designated and
correctly labelled ﬁlter paper and all demographic
information on the sample card has to be ﬁlled in cor-
rectly. Experience shows that all these goals can only be
achieved by regular teaching the staﬀ collecting the
samples; particular attention here is required in
explaining the reasons why the samples have to be col-
lected in a certain way and during a speciﬁc time frame
after birth.
A screening programme can only be successful if the
babies identiﬁed by the system are subjected to timely
and appropriate therapy. Therefore guidance on thera-
peutic measures and management of aﬀected babies
takes an important place in the establishment and
maintenance of quality.
Finally every NBS programme should regularly be
audited to check whether the established goals of the
programme have been achieved. It has been shown that
the publication of such information has a very beneﬁcial
eﬀect on the overall quality.
Logistics and laboratory methodology
The core of a NBS programme is represented by the
analytical procedures. It is therefore evident that the
logistics of the laboratory and the analytical methodol-
ogy take up a major role in the quality planning. Some
of the key requirements for good quality are:
A. Laboratories should be planned to be able to han-
dle a suﬃciently large number of samples in order
to build a signiﬁcant base of experience. This
translates into a number of samples large enough to
provide a regular number of positive and borderline
cases, i.e. one real case every 2–4 weeks; and the
samples should always be assayed on the same day
they arrive in the laboratory. The major conse-
quences arising from a too small number of samples
are:
1. An ineﬃcient screening due to poor cost beneﬁt
ratio and insuﬃcient quality control.
2. Diﬃculties in the correct interpretation of re-
sults, particularly grey-zone or borderline results,
due to little experience and insuﬃcient statistical
data
3. Excessively high number of repeat tests!
B. Care must be taken that the analytical methods used
are:
1. Adequate to reliably detect the disease tested: an
analytical method for NBS has to be reliable at the
ﬁrst analysis. Quite often suﬃcient material for a
repeat test will not be available.
2. Adapted to the local infrastructure: analytical
methods used in NBS diﬀer signiﬁcantly from
country to country due to the diﬀerences in know
how, available resources, ﬁnancial possibilities,
social and economical factors. The ﬁnal result
should remain the same.
3. Remember: quality has its price: low-cost reagents
are not always the most economical. Excessive
savings on the reagents and instrument side are in
our experience usually coupled with high recall
and/or repeat rates, frequent instrument break-
downs and as a consequence higher total costs.
The ﬁnal outcome will always be: poor overall
quality of the programme.
C. The laboratory must implement an adequate level
of internal quality control and participate in at least
one external quality control scheme. The require-
ments for internal QC/QA should be planned in a
way to assure the highest possible precision, the
best rate of analytical error detection and the least
number of samples repeated and/or rejected. Typi-
cally for QC monitoring, all assays where the
internal QC samples are outside the ±2SD limits
are rejected. This rule is in our opinion too strict
and will result in unnecessary assay rejections. In
fact with a ±2SD rule, 5% of the assays will be
rejected even when everything is otherwise in order.
Today there are several software packages available
which facilitate the planning of analytical quality
based on the real performance characteristics of the
analytical method used [3]. With such software,
stricter and statistically more viable rejection limits
can be deﬁned, resulting in an overall better ana-
lytical performance. The key to good results is the
precision, sensitivity and speciﬁcity of the assay
used.
General considerations
A score of initiatives aimed at improving all aspects of
quality in NBS are underway internationally: stan-
dardisation of the ﬁlter paper used for sampling,
guidelines to the choice of the ‘‘ideal’’ time for the col-
lection of the screening sample, deﬁnition and use of
calibrators and reference preparations, ﬂow-sheets for
Table 1 Main components of NBS and measures taken to achieve
quality
NBS component: QC/QA achieved by:
Sample collection Education, information and logistics
Sample transport Logistics
Sample analysis Methodology and logistics
Recall of aﬀected babies Education, information and logistics
Treatment and follow-up Education and information
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recall procedures, guidelines for treatment procedures
and for auditing of the screening system.
Even if numerous national and international organi-
sations are involved in these initiatives, the major steps
for obtaining and maintaining a high quality standard
have to be undertaken at the level of every single pro-
gramme. It is the work at the local level that mostly
inﬂuences the outcome of neonatal screening and allows
to achieve and maintain the level of quality necessary
for an eﬀective performance, all for the beneﬁt of the
aﬀected babies detected through screening.
Conclusions
Quality in NBS, and not only in NBS, is a ‘‘cultural
problem’’. Quality cannot be established and maintained
simply by following blindly a set of rules; quality is an
attitude and must be part of every days life. Only if all
individuals involved in screening take responsibility for
their work, take pride in what they do and are highly
motivated then there will be a substantial improvement
in quality.
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